CareSet supercharges pharma marketing initiatives as the first company commercializing 100% of Medicare A, B and D claims
CareSet Journal
CareSet Journal houses CareSet’s Healthcare Data Journalism work, including our recent work on COVID with the Wall Street Journal.
Part D Targeting Data. Complete Market Transparency.
New Medicare Part D Targeting subscription datasets offer census level accuracy.
Do doctors force their patients to use fax? A CareSet Journal FOIA Whitepaper
Introduction Do patients benefit from the money that the U.S. Government has spent on the interoperability of clinical systems? The Centers for Medicare and Medicaid Services (CMS) believes that the purpose of the $34 billion dollar Electronic Health Record (EHR)…
From the Blog View All Posts
Finding, Treating, and Curing Rare Diseases
Picture the following scenario: A patient presents with symptoms including numbness, tremors, and occasional weakness, among others. Genetic testing exists to check for rare cardiovascular diseases and defects, but it is expensive and not currently listed as part of the…
In the News View All News
CareSet to present at Pharma-SOS and PMSA in Las Vegas in 2022
CareSet is pleased to announce our support and sponsorship of the 2nd Annual Pharma Socialize Optimize Strategize (Pharma-SOS) conference. The conference specializes in data and operations that impact field force efficiency and allows attendees to share best practices and learn…
Latest Posts
Transparency in Specialty Pharmacy Supply Chains
Navigating the world of Specialty Pharmacy is complex and riddled with information asymmetry. But, it just got a lot easier. CareSet provides the experience and unblocked data to connect your new medication with the Specialty Pharmacies and prescribing physicians you need to reach your target patient populations. Characterizing the industry, the co-founder and former president…
Unblocking Part D, MarketView
In specialty pharmacies, some medications may have partially blocked data. Manufacturers, payers, and specialty pharmacies can elect to block this data. When they do, it’s no longer visible to their allied and competitive healthcare stakeholders, like yourself. CareSet’s Part D Targeting product provides brand teams clarity using Medicare’s unblocked claims data. This allows us to…
CareSet’s Part D Targeting Data Offers Complete Market Transparency
New Medicare Part D Targeting subscription datasets offer census level accuracy. New Part D Targeting subscription datasets are now available from CareSet to aid pharma marketing decisions. These datasets supercharge patient’s access to specialty treatments by revealing data that is blocked in commercial datasets. CareSet receives Part D data two weeks after Medicare approves the…
NCPDP PTI Roundtable for VBA
On 8/30/21, I had the honor of co-chairing the first roundtable from NCPDP’s (National Council for Prescription Drug Programs) PharmTechnology Innovation (PTI) Accelerator. Our presenters discussed the different elements related to value-based agreements (VBA). Our incredible speakers included: John W. Hill, MBAHCM, CNED, Executive Vice President & GM with the National Council for Prescription Drug…
Do doctors force their patients to use fax? A CareSet Journal FOIA Whitepaper
Introduction Do patients benefit from the money that the U.S. Government has spent on the interoperability of clinical systems? The Centers for Medicare and Medicaid Services (CMS) believes that the purpose of the $34 billion dollar Electronic Health Record (EHR) Incentive Programs (aka “Meaningful Use”), is to provide patients with access to their medical records…
Updated HOP Teaming Dataset Released During PMSA 2021
The HOP Teaming Dataset from CareSet offers the most detailed and up-to-date picture of the patient-sharing relationships found between all U.S. Medicare providers HOUSTON – CareSet released the updated HOP Teaming Dataset during the Pharmaceutical Management Science Association (PMSA) 2021 Annual Conference. The release is a game-changing dataset that offers the most detailed and up-to-date…
CareSet gets accelerated access to Medicare data to perform COVID data analysis
CareSet is proud to announce that we are now the FIRST (that we know of) company with access to fee-for-service claims data (Part A, B & D), refreshed monthly, and with an industry best 2-week lag. CareSet is using this data to perform analysis of the ongoing COVID pandemic, and how it impacts Medicare patients…
Transparency victories regarding facility-level COVID data
HHS has recently released data about vaccinated personnel at different hospitals. They have also released a new “master key” that helps to identify how hospitals are being enumerated as part of the COVID reporting system. Both of these new data resources have been made public as part of the collaboration that CareSet and other data…
NPI to contact domain data release
CareSet Journal is releasing data that links NPI records to the contact domains submitted by providers in their NPI applications. For example, when Jane Smith applied for an NPI, she provided a contact email of “jane.smith@examplehospital.com”. In this data, her NPI will be listed alongside the domain of “examplehospital.com”. If you want to dive straight…
CareSet at SXSW 2021
At SXSW 2021, presented by Energizing Health. CareSet’s Ashish Patel moderates a panel featuring CareSet CTO Fred Trotter, HHS Chief Data Officer (Acting) Kevin Duvall, and University of Minnesota Carlson School of Management Professor Pinar Karaca Mandic, Ph.D.
I got the COVID-19 vaccine and this is what happened
I am a Mexicana, and I participated in one of the SARS-CoV-2 vaccine trials! Unfortunately, I was a placebo arm. Now, I’m fully vaccinated! This is my experience after receiving both injections. There have been efforts by the FDA to increase the participation of historically underrepresented groups in clinical trials. Kaiser Health News discussed how…
Finally Unblinded from the COVID-19 Vaccine Trial
September 2020, I made the decision to participate in one of the SARS-CoV-2 vaccine trials. There is still vaccine hesitancy. My participation in this trial, along with my blog posts, are all in hopes of increasing transparency, and building trust within the trial community. You can follow my journey beginning with my first blog. When…